United Therapeutics Corporation Research and Development Expense
United Therapeutics Corporation (UTHR) reported Research and Development Expense of $146.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- United Therapeutics Corporation research and development expense for the quarter ending 2026-06-30 was $146.30M, a 9.18% increase year-over-year.
- United Therapeutics Corporation research and development expense for the quarter ending 2026-03-31 was $138.20M, a 7.25% decline year-over-year.
- United Therapeutics Corporation research and development expense for the quarter ending 2025-12-31 was $139.50M, a 4.26% increase year-over-year.
- United Therapeutics Corporation research and development expense for the quarter ending 2025-09-30 was $127.50M, a 23.19% increase year-over-year.
- United Therapeutics Corporation research and development expense for fiscal 2025 was $550.00M, a 14.35% increase from fiscal 2024.
- United Therapeutics Corporation research and development expense for fiscal 2024 was $481.00M, a 17.89% increase from fiscal 2023.
- United Therapeutics Corporation research and development expense for fiscal 2023 was $408.00M, a 26.35% increase from fiscal 2022.
- United Therapeutics Corporation research and development expense for fiscal 2022 was $322.90M, a 40.21% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $146.30M 10-Q · filed 2026-08-05 | $284.50M 10-Q · filed 2026-08-05 | $424.00M derived: sum of 3 quarters · filed 2026-08-05 | $551.50M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $138.20M 10-Q · filed 2026-05-06 | $277.70M derived: sum of 2 quarters · filed 2026-05-06 | $405.20M derived: sum of 3 quarters · filed 2026-05-06 | $539.20M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $139.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $267.00M derived: sum of 2 quarters · filed 2026-02-25 | $401.00M derived: sum of 3 quarters · filed 2026-08-05 | $550.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $127.50M 10-Q · filed 2025-10-29 | $261.50M derived: sum of 2 quarters · filed 2026-08-05 | $410.50M 10-Q · filed 2025-10-29 | $544.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $134.00M 10-Q · filed 2026-08-05 | $283.00M 10-Q · filed 2026-08-05 | $416.80M derived: sum of 3 quarters · filed 2026-08-05 | $520.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $149.00M 10-Q · filed 2026-05-06 | $282.80M derived: sum of 2 quarters · filed 2026-05-06 | $386.30M derived: sum of 3 quarters · filed 2026-05-06 | $525.90M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $133.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $237.30M derived: sum of 2 quarters · filed 2026-02-25 | $376.90M derived: sum of 3 quarters · filed 2026-02-25 | $481.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $103.50M 10-Q · filed 2025-10-29 | $243.10M derived: sum of 2 quarters · filed 2025-10-29 | $347.20M 10-Q · filed 2025-10-29 | $498.60M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $139.60M 10-Q · filed 2025-07-30 | $243.70M 10-Q · filed 2025-07-30 | $395.10M derived: sum of 3 quarters · filed 2026-02-25 | $479.80M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $104.10M 10-Q · filed 2025-04-30 | $255.50M derived: sum of 2 quarters · filed 2026-02-25 | $340.20M derived: sum of 3 quarters · filed 2026-02-25 | $429.20M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $151.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $236.10M derived: sum of 2 quarters · filed 2026-02-25 | $325.10M derived: sum of 3 quarters · filed 2026-02-25 | $408.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $84.70M 10-Q · filed 2024-10-30 | $173.70M derived: sum of 2 quarters · filed 2024-10-30 | $256.60M 10-Q · filed 2024-10-30 | $350.50M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $89.00M 10-Q · filed 2024-07-31 | $171.90M 10-Q · filed 2024-07-31 | $265.80M derived: sum of 3 quarters · filed 2025-02-26 | $331.90M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $82.90M 10-Q · filed 2024-05-01 | $176.80M derived: sum of 2 quarters · filed 2025-02-26 | $242.90M derived: sum of 3 quarters · filed 2025-02-26 | $336.80M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $93.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $160.00M derived: sum of 2 quarters · filed 2025-02-26 | $253.90M derived: sum of 3 quarters · filed 2025-02-26 | $322.90M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $66.10M 10-Q · filed 2023-11-01 | $160.00M derived: sum of 2 quarters · filed 2023-11-01 | $229.00M 10-Q · filed 2023-11-01 | $311.90M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $93.90M 10-Q · filed 2023-08-02 | $162.90M 10-Q · filed 2023-08-02 | $245.80M derived: sum of 3 quarters · filed 2024-02-21 | $325.00M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $69.00M 10-Q · filed 2023-05-03 | $151.90M derived: sum of 2 quarters · filed 2024-02-21 | $231.10M derived: sum of 3 quarters · filed 2024-02-21 | $305.40M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $82.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $162.10M derived: sum of 2 quarters · filed 2024-02-21 | $236.40M derived: sum of 3 quarters · filed 2024-02-21 | $540.10M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $79.20M 10-Q · filed 2022-11-02 | $153.50M derived: sum of 2 quarters · filed 2022-11-02 | $457.20M 10-Q · filed 2022-11-02 | $583.30M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $74.30M 10-Q · filed 2022-08-03 | $378.00M 10-Q · filed 2022-08-03 | $504.10M derived: sum of 3 quarters · filed 2023-02-22 | $572.80M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $303.70M 10-Q · filed 2022-05-04 | $429.80M derived: sum of 2 quarters · filed 2023-02-22 | $498.50M derived: sum of 3 quarters · filed 2023-02-22 | $588.20M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $126.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $194.80M derived: sum of 2 quarters · filed 2023-02-22 | $284.50M derived: sum of 3 quarters · filed 2023-02-22 | $357.70M 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $68.70M 10-Q · filed 2021-11-03 | $158.40M derived: sum of 2 quarters · filed 2021-11-03 | $231.60M 10-Q · filed 2021-11-03 | $345.20M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $89.70M 10-Q · filed 2021-08-04 | $162.90M 10-Q · filed 2021-08-04 | $276.50M derived: sum of 3 quarters · filed 2022-02-24 | $362.20M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $73.20M 10-Q · filed 2021-05-05 | $186.80M derived: sum of 2 quarters · filed 2022-02-24 | $272.50M derived: sum of 3 quarters · filed 2022-02-24 | $358.40M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $113.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $199.30M derived: sum of 2 quarters · filed 2022-02-24 | $285.20M derived: sum of 3 quarters · filed 2022-02-24 | $1.18B 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $85.70M 10-Q · filed 2020-10-28 | $171.60M derived: sum of 2 quarters · filed 2020-10-28 | $1.07B 10-Q · filed 2020-10-28 | $1.21B derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $85.90M 10-Q · filed 2020-07-29 | $983.30M 10-Q · filed 2020-07-29 | $1.12B derived: sum of 3 quarters · filed 2021-02-24 | $1.22B derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $897.40M 10-Q · filed 2020-04-29 | $1.04B derived: sum of 2 quarters · filed 2021-02-24 | $1.14B derived: sum of 3 quarters · filed 2021-02-24 | $1.22B derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $138.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $239.90M derived: sum of 2 quarters · filed 2021-02-24 | $322.20M derived: sum of 3 quarters · filed 2021-02-24 | $357.90M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $101.10M 10-Q · filed 2019-10-30 | $183.40M derived: sum of 2 quarters · filed 2019-10-30 | $219.10M 10-Q · filed 2019-10-30 | |||||
| 2018-06-30 | $82.30M 10-Q · filed 2019-07-31 | $118.00M 10-Q · filed 2019-07-31 | ||||||
| 2018-03-31 | $35.70M 10-Q · filed 2019-05-01 | |||||||
| 2017-12-31 | $264.60M 10-K · filed 2020-02-26 | |||||||
| 2016-12-31 | $66.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $112.80M derived: sum of 2 quarters · filed 2019-02-27 | $147.60M 10-K · filed 2019-02-27 | |||||
| 2016-09-30 | $45.90M 10-Q · filed 2016-10-27 | $80.70M 10-Q · filed 2016-10-27 | ||||||
| 2015-12-31 | $75.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $85.50M derived: sum of 2 quarters · filed 2018-02-21 | $134.91M derived: sum of 3 quarters · filed 2018-02-21 | $245.10M 10-K · filed 2018-02-21 | $245.10M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $9.60M 10-Q · filed 2016-10-27 | $9.53M 10-Q · filed 2015-10-27 | $59.01M derived: sum of 2 quarters · filed 2016-10-27 | $169.20M 10-Q · filed 2016-10-27 | $169.15M 10-Q · filed 2015-10-27 | $240.66M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-06-30 | $49.41M 10-Q · filed 2015-07-28 | $159.62M 10-Q · filed 2015-07-28 | $231.06M derived: sum of 3 quarters · filed 2017-02-22 | $349.93M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2015-03-31 | $110.21M 10-Q · filed 2015-04-28 | $181.65M derived: sum of 2 quarters · filed 2017-02-22 | $300.52M derived: sum of 3 quarters · filed 2017-02-22 | $340.26M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2014-12-31 | $71.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $190.31M derived: sum of 2 quarters · filed 2017-02-22 | $230.05M derived: sum of 3 quarters · filed 2017-02-22 | $242.50M 10-K · filed 2017-02-22 | $242.55M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $118.88M 10-Q · filed 2015-10-27 | $158.62M derived: sum of 2 quarters · filed 2015-10-27 | $171.07M 10-Q · filed 2015-10-27 | $292.62M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $39.74M 10-Q · filed 2015-07-28 | $52.19M 10-Q · filed 2015-07-28 | $173.74M derived: sum of 3 quarters · filed 2016-02-25 | $246.49M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $12.45M 10-Q · filed 2015-04-28 | $134.00M derived: sum of 2 quarters · filed 2016-02-25 | $206.75M derived: sum of 3 quarters · filed 2016-02-25 | $261.37M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $121.55M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $194.30M derived: sum of 2 quarters · filed 2016-02-25 | $248.92M derived: sum of 3 quarters · filed 2016-02-25 | $299.35M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $72.75M 10-Q · filed 2014-10-28 | $127.37M derived: sum of 2 quarters · filed 2014-10-28 | $177.80M 10-Q · filed 2014-10-28 | $215.27M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $54.62M 10-Q · filed 2014-07-29 | $105.05M 10-Q · filed 2014-07-29 | $142.52M derived: sum of 3 quarters · filed 2015-02-24 | $207.68M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $50.43M 10-Q · filed 2014-04-29 | $87.91M derived: sum of 2 quarters · filed 2015-02-24 | $153.06M derived: sum of 3 quarters · filed 2015-02-24 | $190.16M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $37.48M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $102.63M derived: sum of 2 quarters · filed 2015-02-24 | $139.73M derived: sum of 3 quarters · filed 2015-02-24 | $173.39M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $65.16M 10-Q · filed 2013-10-29 | $102.25M derived: sum of 2 quarters · filed 2013-10-29 | $135.91M 10-Q · filed 2013-10-29 | $184.55M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $37.10M 10-Q · filed 2013-07-25 | $70.76M 10-Q · filed 2013-07-25 | $119.39M derived: sum of 3 quarters · filed 2014-02-25 | $178.82M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $33.66M 10-Q · filed 2013-04-25 | $82.29M derived: sum of 2 quarters · filed 2014-02-25 | $141.73M derived: sum of 3 quarters · filed 2014-02-25 | $165.97M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $48.64M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $108.07M derived: sum of 2 quarters · filed 2014-02-25 | $132.31M derived: sum of 3 quarters · filed 2014-02-25 | $180.01M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $59.43M 10-Q · filed 2012-11-01 | $83.67M derived: sum of 2 quarters · filed 2012-11-01 | $131.38M 10-Q · filed 2012-11-01 | $193.29M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $24.24M 10-Q · filed 2012-07-26 | $71.95M 10-Q · filed 2012-07-26 | $133.86M derived: sum of 3 quarters · filed 2013-02-26 | $174.20M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $47.71M 10-Q · filed 2012-04-26 | $48.03M 10-Q · filed 2011-04-28 | $109.62M derived: sum of 2 quarters · filed 2013-02-26 | $149.96M derived: sum of 3 quarters · filed 2013-02-26 | $178.55M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | $61.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $102.25M derived: sum of 2 quarters · filed 2013-02-26 | $130.84M derived: sum of 3 quarters · filed 2013-02-26 | $165.31M 10-K · filed 2013-02-26 | $166.76M 10-K · filed 2011-02-24 | |||
| 2010-09-30 | $40.34M 10-Q · filed 2011-10-27 | $40.69M 10-Q · filed 2010-10-28 | $68.92M derived: sum of 2 quarters · filed 2011-10-27 | $103.39M 10-Q · filed 2011-10-27 | $104.51M 10-Q · filed 2010-10-28 | $143.01M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-06-30 | $28.59M 10-Q · filed 2011-07-28 | $28.94M 10-Q · filed 2010-07-28 | $63.05M 10-Q · filed 2011-07-28 | $63.81M 10-Q · filed 2010-07-28 | $102.67M derived: sum of 3 quarters · filed 2012-02-28 | $134.22M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-03-31 | $34.87M 10-Q · filed 2011-04-28 | $74.08M derived: sum of 2 quarters · filed 2012-02-28 | $105.63M derived: sum of 3 quarters · filed 2012-02-28 | $134.28M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2009-12-31 | $39.21M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $70.76M derived: sum of 2 quarters · filed 2012-02-28 | $99.41M derived: sum of 3 quarters · filed 2012-02-28 | $120.37M 10-K · filed 2012-02-28 | $122.19M 10-K · filed 2011-02-24 | |||
| 2009-09-30 | $31.55M 10-Q · filed 2010-10-28 | $60.20M derived: sum of 2 quarters · filed 2010-10-28 | $81.16M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $28.65M 10-Q · filed 2010-07-28 | $49.60M 10-Q · filed 2010-07-28 | ||||||
| 2008-12-31 | $239.18M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |